rf IDEAS Launches End-to-End FIDO2 Credential Solution with IDmelon
rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, is pleased to announce the release of the rf IDEAS FIDO2 Passwordless Platform powered by IDmelon. This end-to-end solution brings seamless, passwordless authentication to existing credentials by converting them to FIDO2 security keys – overnight.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005278/en/
FIDO2 frees organizations from password management and risk
Nearly 90% of data breaches are due to stolen passwords or human error. Passwordless single-sign on solutions are helping to combat this challenge, and migrating to more secure credentials helps arm your team with a defense mechanism.
“Partnering with rf IDEAS, and their WAVE ID® technology was a strategic decision for IDmelon – leveraging the trust and reliability of their readers to bring the FIDO2 Passwordless Platform to market allows us to jointly deliver an end-to-end solution that organizations can deploy quickly and scale affordably,” remarked CEO and co-founder of IDmelon Bahram Piri.
The rf IDEAS FIDO2 Passwordless Platform eliminates the need for centrally stored passwords that can be hacked, as well as the risk of password theft, phishing and other user-directed cyberattacks. And for users, it’s simple to roll out and easy to use. Organizations can now enable and manage passwordless authentication across credential types, devices and platforms. This rapidly growing industry standard is supported by Microsoft, Google, Apple, and all leading web services and browsers.
Ushering in a new standard for authentication
The logical access control industry is evolving rapidly to combat cyber threats and data breaches while improving the user experience of authentication without risking governance and security.
“At rf IDEAS, we have listened to our customers and are proud to release a solution that removes the complexities of credential migration, converting users quickly and securely to a higher standard of security,” said Raul Cepeda Jr., Vice President of Product and Marketing at rf IDEAS. “Now, access via security keys is possible using existing credentials, WAVE ID readers, and the rf IDEAS Passwordless Platform – evolving the way we think about migration across credentials by leveraging ID badges and smartphones to unlock potential to more secure authentication methods.”
rf IDEAS and IDmelon will be showcasing their joint solution at the upcoming Gartner IAM symposiums in London and Texas this month – to see a full listing of upcoming events visit our Events Page.
To learn more and set up a 1:1 consultation, visit rfIDEAS.com/FIDO2.
About rf IDEAS
rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, financial, government, education and enterprise. The company’s WAVE ID readers are trusted by users across the globe and backed by strong partnerships with leading identity and access management providers. rf IDEAS readers enable innovative solutions for single sign-on, secure printing, and mobile authentication while supporting nearly all credentials worldwide. For more information, visit www.rfIDEAS.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005278/en/
Contact information
Megan Forsberg
P: 224-236-0270 x 1479
E: mforsberg@rfIDEAS.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
